Mark Thomas Esser
Impact in
- Epidemiology top 0.1%
- Cervical Cancer and HPV Research
- Hepatitis B Virus Studies
- Respiratory viral infections research
- Pneumonia and Respiratory Infections
- Infectious Diseases top 1%
- SARS-CoV-2 and COVID-19 Research
- Viral gastroenteritis research and epidemiology
Papers in
- Epidemiology 66
- Respiratory viral infections research 34
- Cervical Cancer and HPV Research 29
- Pneumonia and Respiratory Infections 12
- Hepatitis B Virus Studies 8
-
- SARS-CoV-2 and COVID-19 Research 24
- Viral gastroenteritis research and epidemiology 11
- Co-authors
- Eliav Barr (9 shared papers)Janine T. Bryan (6 shared papers)Tonya L. Villafana (15 shared papers)Filip Dubovsky (9 shared papers)Frank J. Taddeo (4 shared papers)Therese Takas (6 shared papers)Heather L. Sings (2 shared papers)M. Pamela Griffin (5 shared papers)
- Journals
- Clinical and Vaccine Immunology (9 papers)Open Forum Infectious Diseases (6 papers)Nature Communications (5 papers)PLoS ONE (5 papers)The Journal of Infectious Diseases (5 papers)
- Partner nations
- United StatesUnited KingdomNetherlands
In The Last Decade
Mark Thomas Esser
124 papers receiving 11.1k citations
Mark Thomas Esser's Hit Papers
Peers
Comparison fields: 5 of 134
- Epidemiology 8.1k
- Infectious Diseases 2.1k
- Immunology 2.0k
- Virology 434
- Microbiology 553
Countries citing papers authored by Mark Thomas Esser
This map shows the geographic impact of Mark Thomas Esser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Thomas Esser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Thomas Esser more than expected).
Fields of papers citing papers by Mark Thomas Esser
This network shows the impact of papers produced by Mark Thomas Esser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Thomas Esser. The network helps show where Mark Thomas Esser may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Thomas Esser, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 128 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases Hit paper breakdown → | 2007 | 1545 |
| 2 | Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial Hit paper breakdown → | 2005 | 1280 |
| 3 | High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up Hit paper breakdown → | 2006 | 663 |
| 4 | Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants Hit paper breakdown → | 2020 | 583 |
| 5 | 2007 | 447 | |
| 6 | 2009 | 405 | |
| 7 | 2007 | 382 | |
| 8 | 2006 | 377 | |
| 9 | 2007 | 258 | |
| 10 | 2003 | 257 | |
| 11 | 2005 | 223 | |
| 12 | 2021 | 209 | |
| 13 | 2018 | 184 | |
| 14 | Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2022 | 168 |
| 15 | The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans Hit paper breakdown → | 2022 | 162 |
| 16 | 2010 | 155 | |
| 17 | 2003 | 151 | |
| 18 | 2001 | 150 | |
| 19 | 2021 | 147 | |
| 20 | 2016 | 125 |
About Mark Thomas Esser
Mark Thomas Esser is a scholar working on Epidemiology, Infectious Diseases, Immunology, Pulmonary and Respiratory Medicine and Virology, having authored 128 papers that have together received 11.8k indexed citations. Recurring topics across this work include Respiratory viral infections research (34 papers), Cervical Cancer and HPV Research (29 papers), SARS-CoV-2 and COVID-19 Research (24 papers), Pneumonia and Respiratory Infections (12 papers), Immune Cell Function and Interaction (11 papers), Viral gastroenteritis research and epidemiology (11 papers), Immunotherapy and Immune Responses (11 papers) and Hepatitis B Virus Studies (8 papers). The work is most often cited by research in Epidemiology (8.1k citations), Infectious Diseases (2.1k citations), Immunology (2.0k citations), Virology (434 citations) and Microbiology (553 citations). Mark Thomas Esser has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Eliav Barr, Janine T. Bryan, Tonya L. Villafana, Filip Dubovsky, Frank J. Taddeo, Therese Takas, Heather L. Sings, M. Pamela Griffin, Carlos A. Sattler and Cosette Marie Wheeler. Their work appears in journals such as Clinical and Vaccine Immunology, Open Forum Infectious Diseases, Nature Communications, PLoS ONE and The Journal of Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.